Why Milestone Pharmaceuticals Inc.’s (MIST) Stock Is Down 12.23%
As of Friday, November 13, Milestone Pharmaceuticals Inc.’s MIST share price has dipped by 12.23%, which has investors questioning if this is right time to buy.Rosalio Madrigal
| SECTOR | INDUSTRY |
| Health Care | Pharmaceuticals |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Rosalio Madrigal
Michael Rose
Jenna Brashear
Michael Rose
Rosalio Madrigal
| Share Statistics | MIST | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $73.3 | $447.9 | 20% |
|
| Shares Out (Mil) | 138.7 | 46.7 | 69% |
|
| Institutional Ownership | 96.8% | 80.9% | 71% |
|
| Float (Mil) | 106.2 | 46.8 | 61% |
|
| Beta | 0.98 | 0.74 | 58% |
|
| Avg Daily Volume (000s) | 1,953 | 342 | 79% |
|
| Price Change (52-week) |
(73.1%) | 54.7% | 11% |
|
| Growth | MIST | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.1% | na |
|
| Net Income (5yr) | (4.8%) | (1.6%) | 34% |
|
| EPS (5yr) | 15.1% | 15.0% | 57 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | 18.7% | (15.1%) | 78% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 5 | 5 | |
| Current EPS | ($0.210) | ($0.832) | ($0.754) | |
| Month Ago EPS | ($0.212) | ($0.838) | ($0.772) | |
| # Rev Up | 1 | 1 | 0 | |
| # Rev Down | 0 | 0 | 1 | |
| Three Months Ago EPS | ($0.208) | ($0.823) | ($0.778) | |
| Year/Year Chg | 1.9% | 10.6% | (68.8%) | |
| Financials | MIST | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $2 | $303 | 3% |
|
| Net Income (TTM) (Mil) | ($84) | ($10) | 12% |
|
| EPS (TTM) | ($0.712) | ($0.600) | 24% |
|
| Operating Cash Flow (TTM) (Mil) | ($61) | ($7) | 9% |
|
| Net Cash Flow (TTM) (Mil) | $127 | $1 | 80% |
|
| Long-Term Debt (Q1) (Mil) | $141 | $6 | 46% |
|
| Enterprise Value (Q1) (Mil) | $83 | $408 | 20% |
|
| Valuation | MIST | Industry Median |
Percentile (All Stocks) |
|
| P/B | 4.00 | 2.19 | 76% |
|
| P/E | na | 22.1 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.2 | na |
|
| Ratios | MIST | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 98.0% | 69.5% | 96% |
|
| Net Margin | na | 3.9% | na |
|
| ROA | (73.4%) | (22.7%) | 8% |
|
| ROE | na | (25.0%) | na |
|
| Liabilities to Assets | 90.0% | 31.8% | 86% |
|
| F-Score | 3 | 3 | 18% |
|
Milestone Pharmaceuticals Inc. did not pass any screens on 11/13/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors